Phaarmasia Ltd

Phaarmasia has announced its financial results for the quarter ending December 2024, revealing stable performance. The company's evaluation score has been adjusted to -5 from -6 over the past three months, reflecting its current market standing as it navigates the pharmaceuticals sector.

Phaarmasia, a microcap pharmaceutical company, has reported a decline in its financial performance for the quarter ending September 2024. While there has been an improvement in profitability, there are concerning factors such as a decrease in net sales and operating profit. Investors should carefully evaluate these results before making any investment decisions.

Phaarmasia, a microcap pharmaceutical company, has reported a flat performance in the first quarter of 2024, with a score of 5 out of 10. However, there are positive signs such as a 27.12% increase in net sales and a higher Profit After Tax of Rs 0.75 crore, indicating potential for growth in the future.

Phaarmasia, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching a 52-week high of Rs. 64.75 on July 12, 2024. Despite a 'Sell' rating from MarketsMOJO, the stock has outperformed the sector by 4.88% and has been on a consecutive gain for the last 5 days. With a strong momentum and trading above its moving averages, Phaarmasia has shown impressive growth potential and has outperformed the Sensex in the past year.

Phaarmasia, a microcap pharmaceutical company, has seen a significant increase in its share price, reaching a 52-week high on July 11, 2024. Despite a 'Sell' rating from MarketsMOJO, the company has outperformed the sector by 5.04% and has shown consistent growth in the past year. Its current upward trend and strong financials make it a promising player in the pharma industry.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 61.58 on June 28, 2024. Despite a Sell rating from MarketsMOJO, the stock has outperformed the sector and has been on a winning streak for 9 days. Its strong performance and focus on the thriving pharmaceutical industry have caught the attention of investors.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on June 27, 2024. With a consecutive gain of 39.34% in the past 8 days, the stock has outperformed the sector by 4.7%. It opened strong today and is trading higher than its moving averages, indicating a positive trend and potential for growth.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, hitting a 52-week high of Rs. 55.86 on June 26, 2024. The stock has been performing well in the past 7 days, gaining 32.72% and outperforming the sector by 5.22%. It has also shown consistent growth and is trading higher than its moving averages. However, it is important to do thorough research and consult with a financial advisor before making any investment decisions.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 53.05 on June 25th, 2024. The stock has consistently traded at this price, showcasing strong demand from investors. Its impressive performance over the past year and positive trend in price movement indicate potential for growth in the pharmaceutical industry.

Phaarmasia, a microcap pharmaceutical company, has seen a significant increase in its stock price, reaching a 52-week high of Rs. 50.67 on June 24, 2024. The stock has been consistently rising for the past 5 days, outperforming the sector by 4.97%. Its strong performance and positive trend make it a company to watch in the pharma industry. However, according to MarketsMOJO, the stock call for Phaarmasia is 'Sell', highlighting the importance of thorough research before investing.

Phaarmasia, a microcap pharmaceutical company, saw its stock reach a 52-week high on June 21, 2024. The company's stock has been performing well, outperforming the sector by 4.71% and gaining 14.66% in the last four days. This surge can be attributed to the company's strong performance and positive market sentiment. However, MarketsMOJO has given a 'Sell' call for the stock, highlighting the need for investors to do their own research before investing.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on June 20, 2024. The stock has been consistently strong, trading higher than its moving averages and outperforming the sector. Despite a 'Sell' call from MarketsMOJO, Phaarmasia's impressive 1-year performance and potential in the pharmaceutical industry make it an interesting player to watch.

Phaarmasia, a microcap pharmaceutical company, has reported a positive performance in the quarter ending March 2024, with a score of 8 compared to -4 in the previous quarter. The company's net sales have increased by 42.2%, reaching its highest in the last five quarters. Its operating profit and profitability have also shown a positive trend, resulting in a higher EPS. MarketsMOJO has given a 'Sell' call for the company's stock based on these results.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 46.2 on February 14, 2024. Despite a 'Sell' rating from MarketsMOJO, the company has shown impressive performance in the past year, outperforming the sector and trading higher than its moving averages.

Phaarmasia's financial performance for the quarter ending Dec 2023 has been disappointing, with a significant decline in profitability. The company's operating profit, operating profit margin, net profit, and EPS have all fallen by over 90% compared to the previous four quarters. This has led to a 'Sell' call by MarketsMOJO, indicating a negative outlook for the company's stock.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high of Rs. 45.48 on February 13, 2024. The stock has outperformed the sector by 8.2% and has shown consecutive gains for the last 3 days. It is currently trading higher than its moving averages and has a strong 1-year performance of 68.87%.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on February 12th, 2024. The stock has outperformed its sector by 5.63% and gained 10.8% in the last two days. It is currently trading above its moving averages, indicating a bullish trend and reflecting the company's strong financials and growth potential. Despite a 'Sell' call by MarketsMOJO, Phaarmasia has shown impressive performance and potential for future growth.

Phaarmasia, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on February 8th, 2024. Despite a 'Sell' call from MarketsMOJO, the stock has been performing well, outperforming its sector by 4.43% and gaining 19.43% in the last 5 days. Its impressive performance in the last year and positive trend indicate a strong stock performance.